Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?

Emmanuel S. Antonarakis

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?'. Together they form a unique fingerprint.